Novo's global workforce falls by 13,000 amid cost cuts

Novo has reduced its global workforce by approximately 13,000 positions over the past year to cut costs and redirect resources toward R&D. The total includes 9,000 layoffs announced last year alongside 4,000 departures driven primarily by natural attrition and unfulfilled vacancies. The company aims to launch over five major new medicines by 2030.